Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vistusertib + ibrutinib
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Vistusertib + ibrutinib** is a combination of two investigational small molecule inhibitors intended for the treatment of B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL). Vistusertib is a dual inhibitor of mammalian target of rapamycin complexes 1 and 2 (mTORC1/2), targeting key cellular pathways involved in cell growth and survival. Ibrutinib selectively and irreversibly inhibits Bruton’s tyrosine kinase (BTK), a critical enzyme in B-cell receptor signaling, resulting in impaired proliferation and migration of malignant B cells. The combination is designed to target complementary signaling pathways that drive B-cell malignancy and resistance to single-agent therapy. Clinical studies have evaluated various dosing schedules for vistusertib in combination with BTK inhibitors in relapsed/refractory lymphoma, but clinical activity has been modest.
- Other names
- vistusertibibrutinib
02
Targets
BMX (Bone Marrow Tyrosine Kinase X-linked)BTK (Bruton tyrosine kinase)ITK (Interleukin 2-inducible T-cell kinase)JAK3 (Janus kinase 3)Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2
Beyond the preview
Go deeper on vistusertib + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vistusertib + ibrutinib.